Auna stock
AUNANYSEAuna S.A., HealthcareISIN LU2791994721
42Score 42 out of 100, Weak
Price and trend
34 / 100
Price history
−13% in one yearThe chart shows daily closes over 3 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 10% below it.
Since November 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Sharply down: the price has fallen very quickly lately (RSI 29).
The price is 24% below its 52-week high. Largest decline in 3 years: 61% (March 2024 to May 2026).
Chart figures for advanced users
- SMA 50$5.03
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$5.10
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)29
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$4.15
- The lowest closing price of the last twelve months.
- Resistance$5.98
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Auna S.A. belongs to the Medical (Care Facilities) industry (Luxembourg) and, with a market value of $338.24M, is number 53 of 57 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of PEN 4.39B (down 0% year on year) and earnings of PEN 97.61M (down 11.5%).
- MEQIRI Score 42 out of 100 (Weak): rank 500 of 702 in Healthcare, median 53.
Show more
- The P/E is 174.1 (Medical (Care Facilities) median 19.6, own median of recent years 10.6).
- Our model puts fair value at $2.01, with the price 127% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow above 500% of earnings over the last 12 months.
- Share buybacksShare count down 33% since 2020.
- Growing faster than its industryRevenue up 24.9% a year since 2020, Medical (Care Facilities) median 9.2%.Growth 83
Weaknesses
- Richly valuedP/E 174.1, Medical (Care Facilities) median 19.6, own median 10.6.Valuation 26
- Above fair valuePrice 127% above the fair value of $2.01.Valuation 26
- Interest barely coveredOperating profit covers interest only 1.5 times.Stability 37
Its standout strength is growth, while valuation and capital allocation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 43 to 42.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high growth grade (crashed more often in the backtest)
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $1.44 and expensive above $3.35 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $3.51 (cash-flow model) and $0.52 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 8.3%. At 9.3% the fair value would be $1.85, at 7.3% it would be $2.23.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.6).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 7.6% on the twelve months before. Revenue has grown strongly since 2017, at around 25% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 38%, operating 14%, net 2%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 17 Nov 2026in 4 days
- Last reported
- 18 Aug 2026EPS reported 0.15 (expected 0.26)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- 2.61−0.1%
- Revenue
- PEN 4.93B−0.1%
- Earnings per share
- 3.44−0.1%
- Revenue
- PEN 5.22B−0.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook mixed
Share price after the results: −3.1%Revenue guidance of about 12% growth reaffirmed and free cash flow above original expectations, but adjusted EBITDA growth is now expected toward the low end of the 10% to 14% range.
“Based on the underlying performance of the business, we expect adjusted EBITDA growth towards the low end of our 10% to 14% guidance range, excluding the impact of Peru's accepted billing penalties, primarily related to prior year's billing matters.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 19 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $357,009 in total. One insider sold, $73,303 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Zamora Leon JesusPurchase
29 May 2026, President
- Shares
- 6,420
- Price
- $4.15
- Value
- $26,643
- Zamora Leon JesusPurchase
28 May 2026, President
- Shares
- 9,220
- Price
- $4.17
- Value
- $38,447
- Wilton JohnSale
28 May 2026, Board
- Shares
- 17,574
- Price
- $4.17
- Value
- $73,303
Show 4 more
- Zamora Leon JesusPurchase
27 May 2026, President
- Shares
- 23,273
- Price
- $4.20
- Value
- $97,702
- Zamora Leon JesusPurchase
26 May 2026, President
- Shares
- 30,000
- Price
- $4.39
- Value
- $131,700
- Zamora Leon JesusPurchase
26 May 2026, President
- Shares
- 8,727
- Price
- $4.24
- Value
- $36,993
- Zamora Leon JesusPurchase
20 May 2026, President
- Shares
- 5,814
- Price
- $4.39
- Value
- $25,523
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Auna
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 42
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- Strata Critical MedicalSRTA $515.38M46
- M1 KlinikenM12.DE $406.28M74
- Starling OncologySTLN $382.47M26
- Viemed HealthcareVMD $345.21M65
- Community Health SystemsCYH $311.67M34
- LNA SantéLNA.PA $300.08M55
- MediclinMED.DE $284.23M61
- LIMES SchlossklinikenLIK.DE $194.79M73
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.